Literature DB >> 16888717

Metabolite profile of sibutramine in human urine: a liquid chromatography-electrospray ionization mass spectrometric study.

Marek Link1, Kati S Hakala, Vladimír Wsól, Risto Kostiainen, Raimo A Ketola.   

Abstract

We present a detailed experimental approach to detection and subsequent structural characterization of unknown metabolites of sibutramine, using liquid chromatography-mass spectrometric techniques. The full-, precursor ion, and constant neutral loss scan modes of a triple quadrupole mass spectrometer were used for screening sibutramine metabolites in human urine. The structural assessment of unknown metabolites was based on MSn ion trap mass spectrometric analysis and comparison of MSn spectra between the standards and compounds detected. Two phase-I (M1 and M2) and eight phase-II (M3-M6) metabolites of sibutramine were found in human urine. Metabolites M1 and M2, which were found as minor metabolites, originated from N-demethylation of sibutramine. Carbamoyl glucuronides formed from metabolites M1, M2, and their hydroxylated analogs were the main metabolites of sibutramine and were characterized by tandem mass spectrometric analysis and by the chemical modification of their structure. We demonstrate the usefulness of the chemical derivatization approach for estimation of the site of glucuronidation and propose the formation of hydroxylated regioisomers of metabolites M4 and M6. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16888717     DOI: 10.1002/jms.1082

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  4 in total

Review 1.  High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.

Authors:  M Holcapek; L Kolárová; M Nobilis
Journal:  Anal Bioanal Chem       Date:  2008-03-15       Impact factor: 4.142

2.  Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.

Authors:  Peter S Talbot; Stefan Bradley; Cyril P Clarke; Kola O Babalola; Andrew W Philipp; Gavin Brown; Adam W McMahon; Julian C Matthews
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

3.  Exposure-response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development.

Authors:  Seunghoon Han; Sangil Jeon; Taegon Hong; Jongtae Lee; Soo Hyeon Bae; Wan-su Park; Gab-jin Park; Sunil Youn; Doo Yeon Jang; Kyung-Soo Kim; Dong-Seok Yim
Journal:  Drug Des Devel Ther       Date:  2015-09-09       Impact factor: 4.162

Review 4.  New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites.

Authors:  Xingxing Diao; Marilyn A Huestis
Journal:  Front Chem       Date:  2019-03-04       Impact factor: 5.545

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.